LEXX Insider Trading

Insider Ownership Percentage: 7.61%
Insider Buying (Last 12 Months): $5,008.00
Insider Selling (Last 12 Months): $10,268.00

Lexaria Bioscience Insider Trading History Chart

This chart shows the insider buying and selling history at Lexaria Bioscience by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lexaria Bioscience Share Price & Price History

Current Price: $2.34
Price Change: Price Decrease of -0.02 (-0.85%)
As of 10/30/2024 01:04 PM ET

This chart shows the closing price history over time for LEXX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Lexaria Bioscience Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/12/2024Catherine C TurkelDirectorBuy1,600$3.13$5,008.003,100View SEC Filing Icon  
7/31/2024Vanessa CarleinsiderSell2,567$4.00$10,268.00View SEC Filing Icon  
2/9/2023Catherine C TurkelDirectorBuy1,500$2.84$4,260.001,500View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Lexaria Bioscience (NASDAQ:LEXX)

13.06% of Lexaria Bioscience stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at LEXX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Lexaria Bioscience Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/15/2024Armistice Capital LLC1,020,000$2.84M0.0%N/A7.916%Search for SEC Filing on Google Icon
8/9/2024Renaissance Technologies LLC22,800$63K0.0%N/A0.177%Search for SEC Filing on Google Icon
5/16/2024Invenomic Capital Management LP473,265$1.72M0.1%-35.3%3.672%Search for SEC Filing on Google Icon
4/9/2024Welch Group LLC24,000$87K0.0%N/A0.194%Search for SEC Filing on Google Icon
2/14/2024Invenomic Capital Management LP731,981$0.92M0.0%-4.2%7.011%Search for SEC Filing on Google Icon
2/8/2024Cowen AND Company LLC256,327$0.32M0.1%N/A2.455%Search for SEC Filing on Google Icon
11/15/2023Armistice Capital LLC889,272$0.89M0.0%N/A10.992%Search for SEC Filing on Google Icon
8/14/2023Invenomic Capital Management LP766,573$0.56M0.0%+62.0%9.476%Search for SEC Filing on Google Icon
8/8/2022Merit Financial Group LLC21,267$63K0.0%N/A0.357%Search for SEC Filing on Google Icon
2/11/2022Invenomic Capital Management LP359,113$1.45M0.3%+1.9%6.034%Search for SEC Filing on Google Icon
11/15/2021MD Financial Management Inc.407,687$2.55M0.1%+15,078.2%7.988%Search for SEC Filing on Google Icon
8/16/2021Invenomic Capital Management LP317,110$2.22M0.5%+7.1%6.213%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC17,200$0.12M0.0%N/A0.337%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC50,385$0.35M0.0%N/A0.987%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.25,976$0.18M0.0%N/A0.509%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC14,915$84K0.0%N/A0.292%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC14,915$84K0.0%N/A0.292%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Lexaria Bioscience logo
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Read More on Lexaria Bioscience

Today's Range

Now: $2.34
Low: $2.30
High: $2.38

50 Day Range

MA: $3.12
Low: $2.36
High: $3.91

52 Week Range

Now: $2.34
Low: $1.20
High: $6.85

Volume

40,704 shs

Average Volume

273,530 shs

Market Capitalization

$37.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97

Who are the company insiders with the largest holdings of Lexaria Bioscience?

Lexaria Bioscience's top insider investors include:
  1. Catherine C Turkel (Director)
  2. Vanessa Carle (Insider)
Learn More about top insider investors at Lexaria Bioscience.